Supplements

SGLT2 inhibitors reduce acute kidney injury incidence in patients with diabetes mellitus receiving cisplatin chemotherapy

In a retrospective study of 288 patients with diabetes mellitus receiving cisplatin, those taking SGLT2 inhibitors had a significantly lower incidence of acute kidney injury (13.9% vs 28.5%, OR 0.42, 95% CI 0.23-0.76). The SGLT2 inhibitor group also showed higher eGFR at 3 months and lower rates of hypomagnesemia and anemia.

Last updated: Jul 7, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.

observational

Cintrón-García JJ, Patel M, Andersen CR, Page V, Workeneh B, Mandayam S, Al-Dallal R, Abudayyeh A, Mamlouk O · Kidney international reports (2026)

Participants: N/A
Duration: 2 months (median follow-up)
Intervention: SGLT2 inhibitor use at cisplatin initiation (continuation of SGLT2i therapy)
Outcome: Acute kidney injury (≥50% serum creatinine increase within 4 weeks), eGFR at 3 months, hypomagnesemia, hyponatremia, anemia
Effect Size: OR: 0.42; 95% CI: 0.23-0.76
Population: Patients with cancer having diabetes mellitus receiving intravenous cisplatin (n=288, median 5 infusions at 40 mg/m²)

Result:

PubMed: 42179813DOI: 10.1016/j.ekir.2026.106538

Mechanism Graph

SGLT2 inhibitors reduce tubular cell uptake of cisplatin
↓
Decreased cisplatin accumulation in renal tubular cells
↓
Reduced tubular cell injury and apoptosis
↓
Result: Lower incidence of acute kidney injury

Limitations

  • ⚠Retrospective single-center study design limits causal inference
  • ⚠Potential residual confounding despite propensity score matching
  • ⚠Short median follow-up of 2 months may miss longer-term renal outcomes

Frequently Asked Questions

What is the main finding of this study?▼

SGLT2 inhibitor use was associated with a 58% reduction in the odds of acute kidney injury in patients with diabetes receiving cisplatin chemotherapy.

How was acute kidney injury defined in this study?▼

AKI was defined as a ≥50% increase in serum creatinine within 4 weeks of cisplatin administration.

What other benefits were observed in the SGLT2 inhibitor group?▼

The SGLT2 inhibitor group had higher eGFR at 3 months and lower rates of hypomagnesemia and anemia, though the difference in hyponatremia was not statistically significant.

What type of study was this?▼

This was a single-center retrospective observational study with propensity score matching, not a randomized controlled trial.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Cintrón-García JJ, Patel M, Andersen CR, Page V, Workeneh B, Mandayam S, Al-Dallal R, Abudayyeh A, Mamlouk O. "Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.." Kidney international reports, 2026. PMID: 42179813 DOI: 10.1016/j.ekir.2026.106538
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.